EUVIMEDEUVIMED entdecken
Open Access

Exploring β-lactam interactions with DacB1: unraveling optimal therapies for combating drug-resistant Mycobacterium tuberculosis

Mary Nantongo iD, David C Nguyen iD, Eunjeong Shin iD, Christopher R Bethel, Magdalena A Taracila, Khalid M Dousa iD, Qing Li, Shane Fletcher, Sebastian G Kurz, Barry N Kreiswirth iD, W Henry Boom, Steve Holland und 2 weitere

mBio · 2025

DOI: 10.1128/mbio.01372-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift mBio, 2025. Verfasst von Mary Nantongo und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology and Microbiology, Case Western Reserve University (CWRU), Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, beta-Lactams, Tuberculosis, Multidrug-Resistant, Anti-Bacterial Agents. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Institute of Allergy and Infectious Diseases, NIAID NIH HHS, FIC NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tuberculosis (TB) continues to pose a global public health threat, exacerbated by rising drug-resistant strains of Mycobacterium tuberculosis (Mtb). DacB1, a D,D-carboxypeptidase critical in Mtb peptidoglycan biosynthesis, is a promising target for β-lactam antibiotics (BLs), which remain underutilized in TB treatment. Dual BL therapy may enhance efficacy by inactivating multiple targets within the peptidoglyan synthesis pathway. Minimum inhibitory concentrations (MICs) for β-lactams and β-lactamase inhibitors against Mtb H37Ra, H37Rv, and clinical isolates showed that imipenem, meropenem, or tebipenem MICs were reduced when combined with amoxicillin or ceftriaxone or β-lactamase inhibitors such as clavulanate or durlobactam. Timed electrospray ionization mass spectrometry (ESI-MS) captured acyl-enzyme adducts between DacB1 and BLs, revealing binding interactions with carbapenems (imipenem, meropenem, and tebipenem) but not most penicillins or cephalosporins except cloxacillin and cefoxitin. Differential scanning fluorimetry (DSF) combined with circular dichroism (CD) confirmed physical and structural changes in DacB1 upon BL binding despite no alteration in melting temperature. Carbapenem-DacB1 interactions were notably faster with imipenem, likely due to reduced steric hindrance compared to meropenem and tebipenem. Molecular modeling revealed conserved penicillin-binding protein motifs within the active site of DacB1: S 121 XXK124, S176XN178, and K282TG284 (PDB ID # 4PPR). Building on this, molecular docking suggested favorable interactions between these motifs and the carbapenems: the carbapenem carbonyl group aids in positioning within DacB1’s oxyanion hole, ready for acylation, while hydrophobic interactions with the cyclic R2 side chains and C1 methyl groups in meropenem and tebipenem contribute to steric hindrance hence slow acyl-enzyme formation. These findings enhance our understanding of DacB1 inhibition and suggest that carbapenems, particularly in combination therapies, hold promise as effective TB treatments. IMPORTANCE TB remains a significant public health threat, particularly due to the rising prevalence of drug-resistant Mtb strains. Current treatment options for drug-resistant TB are costly, toxic, and often ineffective, necessitating the exploration of alternative therapeutic strategies. This study is of critical importance as it investigates the potential of β-lactam antibiotics (BLs), a class historically considered ineffective against Mtb, for repurposing in TB treatment. By targeting DacB1, a key enzyme in Mtb peptidoglycan biosynthesis, this research provides new insights into the mechanism of β-lactam interactions and their potential to disrupt cell wall synthesis. The findings demonstrate that dual β-lactam therapy and β-lactam/β-lactamase inhibitor combinations enhance antibiotic efficacy, suggesting a promising avenue for combating drug-resistant TB. Furthermore, structural and molecular analyses confirm that carbapenems, particularly imipenem, meropenem, and tebipenem, effectively bind to DacB1, paving the way for optimized treatment strategies. Given the challenges in developing new TB drugs, repurposing β-lactams offers a cost-effective and readily implementable solution to address antimicrobial resistance. This study contributes valuable knowledge that could accelerate the development of novel TB therapies, improve treatment success rates, and ultimately reduce TB-related mortality worldwide.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium tuberculosisbeta-LactamsTuberculosis, Multidrug-ResistantAnti-Bacterial AgentsBacterial ProteinsAntitubercular AgentsMicrobial Sensitivity TestsHumansbeta-Lactamase InhibitorsMolecular Docking SimulationProtein Binding

Stichwörter der Autor:innen

D, D-carboxypeptidasesDrug-resistant TBMycobacterium tuberculosispeptidoglycanβ-lactam antibioticsβ-lactamase inhibitors

Substanzen

beta-Lactamsbeta-Lactamase InhibitorsAnti-Bacterial AgentsBacterial ProteinsAntitubercular Agents

Autor:innen und Institutionen

  • Department of Molecular Biology and Microbiology, Case Western Reserve University (CWRU), Cleveland, Ohio, USA.
  • Research Service, Louis Stokes Veterans Affairs Medical Center, Cleveland, Ohio, USA.
  • Division of Infectious Diseases, Department of Pediatrics and Division of Infectious Diseases, Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA.
  • Department of Medicine, CWRU, Cleveland, Ohio, USA.
  • Medical Service, Veterans Affairs Northeast Ohio Healthcare System (VANEOHS), Cleveland, Ohio, USA.
  • Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA.

ORCID-Profile: Mary Nantongo, David C Nguyen, Eunjeong Shin, Khalid M Dousa, Barry N Kreiswirth, Eric J Rubin, Robert A Bonomo

Förderung

  • National Institute of Allergy and Infectious Diseases
  • NIAID NIH HHS
  • FIC NIH HHS
  • NIH HHS
  • National Institutes of Health
  • National Institutes of Health: Fogarty International Center

Zitieren

APA

Nantongo, M., Nguyen, D. C., Shin, E., Bethel, C. R., Taracila, M. A., Dousa, K. M., Li, Q., Fletcher, S., Kurz, S. G., Kreiswirth, B. N., Boom, W. H., Holland, S., Rubin, E. J., & Bonomo, R. A. (2025). Exploring β-lactam interactions with DacB1: unraveling optimal therapies for combating drug-resistant Mycobacterium tuberculosis. mBio. https://doi.org/10.1128/mbio.01372-25

Vancouver

Nantongo M, Nguyen DC, Shin E, Bethel CR, Taracila MA, Dousa KM, et al. Exploring β-lactam interactions with DacB1: unraveling optimal therapies for combating drug-resistant Mycobacterium tuberculosis. mBio. 2025. doi:10.1128/mbio.01372-25

BibTeX
@article{Nantongo2025,
  author = {Nantongo, Mary and Nguyen, David C and Shin, Eunjeong and Bethel, Christopher R and Taracila, Magdalena A and Dousa, Khalid M and Li, Qing and Fletcher, Shane and Kurz, Sebastian G and Kreiswirth, Barry N and Boom, W Henry and Holland, Steve and Rubin, Eric J and Bonomo, Robert A},
  title = {Exploring β-lactam interactions with DacB1: unraveling optimal therapies for combating drug-resistant Mycobacterium tuberculosis},
  journal = {mBio},
  year = {2025},
  doi = {10.1128/mbio.01372-25}
}
Kostenlos starten →